Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Elevar Therapeutics Inc.
Headquarters: Salt Lake City, UT, United States of America
Website: https://elevartherapeutics.co...
Year Founded: 2005
Status: Private
BioCentury | Mar 14, 2025
Data Byte
Ten PDUFA dates on FDA’s March agenda
Upcoming decisions include a label expansion for Alnylam’s Amvuttra, a new siRNA therapy for hemophilia, and more
BioCentury | Dec 10, 2024
Deals
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | Jun 30, 2022
Management Tracks
FDA names Bumpus chief scientist, Marston CMO
Plus Beyer becomes CEO at Kures, and updates from NGM, Apexigen, Achilles and more
BioCentury | May 25, 2022
Management Tracks
Manner becomes CEO of OraSure
Plus Afeyan to chair Rubius, Chroma adds Golumbeski to board, Maraganore as adviser
BioCentury | Oct 28, 2021
Management Tracks
Labinger out as Checkmate CEO
Plus: Travecta, MTS Health Partners, Elevar and Y Combinator
BioCentury | Jul 22, 2021
Management Tracks
Management shuffle at Teva
Plus: ViaCyte, Elevar and Harbour BioMed
BioCentury | Jul 10, 2021
Management Tracks
Jiangsu Hengrui chairman steps down; plus Ovid, Verrica and Elevar
The chairman of Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276), Zhou Yunshu, is resigning for health reasons. Former Chairman Sun Piaoyang, who is now a director, will be interim chairman. As
BioCentury | Jun 2, 2021
Management Tracks
Gubitz replaces Castaldi as CFO at argenx; plus Evelo, Athira, Adverum, Nuvation and more
BioCentury | Jan 21, 2021
Management Tracks
MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar, and Imara
Dynavax Technologies Corp. (NASDAQ:DVAX) hired Kelly MacDonald as SVP and CFO, effective March 1. She succeeds CFO Michael Ostrach, who is retiring after 14 years and will remain with the vaccine
Items per page:
1 - 10 of 12